Advanced lipoprotein profile identifies atherosclerosis better than conventional lipids in type 1 diabetes at high cardiovascular risk
Serés-Noriega T, Ortega E, Giménez M, et al.
NMCD. Pub. online 4 Apr 2023.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Safety and efficacy of an adaptive bolus calculator for type 1 diabetes: a randomised control cross over study
Unsworth R, Armiger R, Jugnee N, et al.
Diabetes Technol Ther. Pub. online 5 Apr 2023.
Leggi
Bergenstal RM, Hachmann-Nielsen E, Kvist K, et al. Diabetes Technol Ther. Pub. online 5 Apr 2023.
Bergenstal RM, Hachmann-Nielsen E, Kvist K, et al.
Diabetes Technol Ther. Pub. online 5 Apr 2023.
Leggi
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial
Yi TW, Wong MMY, Neuen BL, et al.
Diabetes Obes Metab. Pub. online 27 Mar 2023.
Leggi
Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the western denmark heart registry
Mortensen MB, Dzaye O, Bøtker HE, et al.
Circulation. 2023;147(14):1053-1063.
Leggi
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidemia
Ciaraldi TP, Boeder SC, Mudaliar SR, et al.
Diabetes Obes Metab. Pub. online 30 Mar 2023.
Leggi
Influenza: diabetes as a risk factor for severe related-outcomes and the effectiveness of vaccination in diabetic population. A meta-analysis of observational studies
Dicembrini I, Silverii GA, Clerico A, et al.
NMCD. Pub. online, 26 Mar 2023
Leggi
Comprehensive management of type 2 diabetes during pregnancy
Valent AM, Caughey AB
JAMA. 2023;329(12):1022-1023.
Leggi
Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nation-wide population-based comparative safety study
Wang H, Cordiner RLM, Huang Y, et al.
Diabetes Care. 2023;dc221238.
Leggi
Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial
Bue-Valleskey JM, Kazda CM, Ma C, et al.
Diabetes Care. 2023;dc222396.
Leggi